Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lucia Siovitz
Observed name:
L. Siovitz
Institutions:
AbbVie (United States),
AbbVie (Germany)
Observed institutions:
AbbVie (United States),
AbbVie (Germany)
ORCID:
0009-0002-6003-7027
Observed ORCID:
0009-0002-6003-7027
OpenAlex ID:
A5020215682
Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled Trial
2024
·
Joan T. Merrill
, Yoshiya Tanaka
, et al.
·
Arthritis & Rheumatology
·
81
Bridging Fixed Dose to Body Weight-based Regimen of Adalimumab in Paediatric Ulcerative Colitis Using a Pharmacometric Modelling Approach: Case Study with the Phase 3 ENVISION I Trial
2022
·
Sven Stodtmann
, Mong-Jen Chen
, et al.
·
Journal of Crohn s and Colitis
·
3
Population Pharmacokinetics and Exposure‐Response Analyses for Ubrogepant Efficacy and Safety in the Acute Treatment of Migraine: Analysis of Phase 1–3 Studies
2026
·
Sven Stodtmann
, Lucia Siovitz
, et al.
·
The Journal of Clinical Pharmacology
·
1
Pos1137 Pharmacokinetics and Exposure-response Relationships of Upadacitinib or Elsubrutinib Alone or in Combination (abbv-599) in Systemic Lupus Erythematous
2023
·
S. Bhatnagar
, L. Siovitz
, et al.
·
Annals of the Rheumatic Diseases
·
1
PDF
Extrapolating Efficacy of Cariprazine to Pediatric Schizophrenia and Bipolar Mania Through Population Pharmacokinetic Analysis
2026
·
Shams Ismaeil
, Lucia Siovitz
, et al.
·
The Journal of Clinical Pharmacology
Phase 1 Asian PK Study of ABBV-CLS-7262, an eIF2B Activator Being Developed as a Potential Treatment for Amyotrophic Lateral Sclerosis and Vanishing White Matter Disease (P5-11.014)
2024
·
Yi Rang Han
, Paul Malik
, et al.
·
Neurology
Show more works
View as search
Works count:
6
Citation count:
88
H-index:
2
I10-index:
1
Year
Topic
Type